Beta‐site amyloid precursor protein cleaving enzyme 1 (BACE1) as a biological candidate marker of Alzheimer's disease

REFERENCES

• Lin X., Koelsch G., Wu S., Downs D., Dashti A., Tang J. Human aspartic protease memapsin 2 cleaves the beta‐secretase site of beta‐amyloid precursor protein. Proc Natl Acad Sci USA 2000; 97: 1456–60
   PubMed Web of Science ®Google Scholar
• Vassar R., Bennett B. D., Babu‐Khan S., Kahn S., Mendiaz E. A., Denis P., et al. Beta‐secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 1999; 286((5440))735–41
   PubMed Web of Science ®Google Scholar
• Yan R., Bienkowski M. J., Shuck M. E., Miao H., Tory M. C., Pauley A. M., et al. Membrane‐anchored aspartyl protease with Alzheimer's disease beta‐secretase activity. Nature 1999; 402((6761))533–7
   PubMed Web of Science ®Google Scholar
• Sinha S., Anderson J. P., Barbour R., Basi G. S., Caccavello R., Davis D., et al. Purification and cloning of amyloid precursor protein beta‐secretase from human brain. Nature 1999; 402((6761))537–40
   PubMed Web of Science ®Google Scholar
• Lee M. S., Kao S. C., Lemere C. A., Xia W., Tseng H. C., Zhou Y., et al. APP processing is regulated by cytoplasmic phosphorylation. J Cell Biol 2003; 163: 83–95
   PubMed Web of Science ®Google Scholar
• Haniu M., Denis P., Young Y., Mendiaz E. A., Fuller J., Hui J. O., et al. Characterization of Alzheimer's beta ‐secretase protein BACE. A pepsin family member with unusual properties. J Biol Chem 2000; 275((28))21099–106
   PubMed Web of Science ®Google Scholar
• Capell A., Steiner H., Willem M., Kaiser H., Meyer C., Walter J., et al. Maturation and pro‐peptide cleavage of beta‐secretase. J Biol Chem 2000; 275((40))30849–54
   PubMed Web of Science ®Google Scholar
• Huse J. T., Doms R. W. Closing in on the amyloid cascade: recent insights into the cell biology of Alzheimer's disease. Mol Neurobiol 2000; 22: 81–98
   PubMed Web of Science ®Google Scholar
• Yang L. B., Lindholm K., Yan R., Citron M., Xia W., Yang X. L., et al. Elevated beta‐secretase expression and enzymatic activity detected in sporadic Alzheimer disease. Nature Med 2003; 9: 3–4
   PubMed Web of Science ®Google Scholar
• Holsinger R. M., McLean C. A., Beyreuther K., Masters C. L., Evin G. Increased expression of the amyloid precursor beta‐secretase in Alzheimer's disease. Ann Neurol 2002; 51: 783–6
   PubMed Web of Science ®Google Scholar
• Fukumoto H., Cheung B. S., Hyman B. T., Irizarry M. C. Beta‐secretase protein and activity are increased in the neocortex in Alzheimer disease. Arch Neurol 2002; 59: 1381–9
   PubMed Web of Science ®Google Scholar
• Gatta L. B., Albertini A., Ravid R., Finazzi D. Levels of beta‐secretase BACE and alpha‐secretase ADAM10 mRNAs in Alzheimer hippocampus. Neuroreport 2002; 13: 2031–3
   PubMed Web of Science ®Google Scholar
• Holsinger R. M., Lee J. S., Boyd A., Masters C. L., Collins S. J. CSF BACE1 activity is increased in CJD and Alzheimer disease versus [corrected] other dementias. Neurology 2006; 67: 710–12
   PubMed Web of Science ®Google Scholar
• Verheijen J. H., Huisman L. G., van Lent N., Neumann U., Paganetti P., Hack C. E., et al. Detection of a soluble form of BACE‐1 in human cerebrospinal fluid by a sensitive activity assay. Clin Chem 2006; 52: 1168–74
   PubMed Web of Science ®Google Scholar
• Zhong Z., Ewers M., Teipel S., Burger K., Wallin A., Blennow K., et al. Levels of beta‐secretase (BACE1) in cerebrospinal fluid as a predictor of risk in mild cognitive impairment. Arch Gen Psychiatry 2007; 64: 718–26
   PubMed Web of Science ®Google Scholar
• Andreasen N., Vanmechelen E., Vanderstichele H., Davidsson P., Blennow K. Cerebrospinal fluid levels of total‐tau, phospho‐tau and A beta 42 predicts development of Alzheimer's disease in patients with mild cognitive impairment. Acta Neurol Scand 2003; 179: 47–51
   Web of Science ®Google Scholar
• Hampel H., Teipel S. J., Fuchsberger T., Andreasen N., Wiltfang J., Otto M., et al. Value of CSF beta‐amyloid 1‐42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment. Molec Psychiatry 2004; 9: 705–10
   PubMed Web of Science ®Google Scholar
• Herukka S. K., Hallikainen M., Soininen H., Pirttila T. CSF Abeta42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment. Neurology 2005; 64: 1294–7
   PubMed Web of Science ®Google Scholar
• Solfrizzi V., Panza F., Colacicco A. M., D'Introno A., Capurso C., Torres F., et al. Vascular risk factors, incidence of MCI, and rates of progression to dementia. Neurology 2004; 63: 1882–91
   PubMed Web of Science ®Google Scholar
• Jack C. R., Jr, Petersen R. C., Xu Y. C., O'Brien P. C., Smith G. E., Ivnik R. J., et al. Prediction of AD with MRI‐based hippocampal volume in mild cognitive impairment. Neurology 1999; 52: 1397–403
   PubMed Web of Science ®Google Scholar
• Maruyama M., Matsui T., Tanji H., Nemoto M., Tomita N., Ootsuki M., et al. Cerebrospinal fluid tau protein and periventricular white matter lesions in patients with mild cognitive impairment: implications for 2 major pathways. Arch Neurol 2004; 61: 716–20
   PubMedGoogle Scholar
• Farrer L. A., Cupples L. A., Haines J. L., Hyman B., Kukull W. A., Mayeux R., et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta‐analysis. APOE and Alzheimer Disease Meta Analysis Consortium. J Am Med Assoc 1997; 278: 1349–56
   PubMed Web of Science ®Google Scholar
• Skoog I., Davidsson P., Aevarsson O., Vanderstichele H., Vanmechelen E., Blennow K. Cerebrospinal fluid beta‐amyloid 42 is reduced before the onset of sporadic dementia: a population‐based study in 85‐year‐olds. Dementia and geriatric cognitive disorders 2003; 15: 169–76
   PubMed Web of Science ®Google Scholar
• Hanson R. L., Looker H. C., Ma L., Muller Y. L., Baier L. J., Knowler W. C. Design and analysis of genetic association studies to finely map a locus identified by linkage analysis: sample size and power calculations. Ann Hum Genet 2006; 70: 332–49
   PubMed Web of Science ®Google Scholar
• Graff‐Radford N. R., Crook J. E., Lucas J., Boeve B. F., Knopman D. S., Ivnik R. J., et al. Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Arch Neurol 2007; 64: 354–62
   PubMedGoogle Scholar
• Buerger K., Ewers M., Andreasen N., Zinkowski R., Ishiguro K., Vanmechelen E., et al. Phosphorylated tau predicts rate of cognitive decline in MCI subjects: a comparative CSF study. Neurology 2005; 65: 1502–3
   PubMed Web of Science ®Google Scholar
• Buerger K., Zinkowski R., Teipel S. J., Tapiola T., Arai H., Blennow K., et al. Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231. Arch Neurol 2002; 59: 1267–72
   PubMed Web of Science ®Google Scholar
• Ewers M., Buerger K., Teipel S. J., Scheltens P., Schroeder J., Zinkowski R., et al. Multicenter assessment of CSF‐phosphorylated tau for the prediction of conversion of MCI. Neurology 2007; 69: 2205–2212
   PubMed Web of Science ®Google Scholar
• Frank R. A., Galasko D., Hampel H., Hardy J., de Leon M. J., Mehta P. D., et al. Biological markers for therapeutic trials in Alzheimer's disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer's disease. Neurobiol Aging 2003; 24: 521–36
   PubMed Web of Science ®Google Scholar